Navigation Links
Aton Pharma Acquires Parkinson's Drug LODOSYN(R) (carbidopa)
Date:4/26/2010

symptoms. The drug combination works as a dopamine regulator, by increasing dopamine and assuring it stays within the brain. Carbidopa is given with levodopa to prevent it from being converted into dopamine outside the brain, helping prevent the side-effects of nausea and vomiting that occur when too much dopamine is outside of the brain. In addition, carbidopa decreases the amount of levodopa needed. Together, the two drugs provide an increase in dopamine in the brain, which is thought to be the mechanism whereby levodopa relieves symptoms of Parkinson's disease.

LODOSYN is supplied by a 25 mg tablet in a bottle of 100 tablets. Aton Pharma, Inc. will now assume exclusive responsibility for its U.S. sales and distribution.

About LODOSYN

LODOSYN (carbidopa), an inhibitor of aromatic amino acid decarboxylation, is indicated for use with carbidopa-levodopa or with levodopa in the treatment of the symptoms of idiopathic Parkinson's disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism. LODOSYN is for use with carbidopa-levodopa in patients for whom the dosage of carbidopa-levodopa provides less than adequate daily dosage (usually 70 mg daily) of carbidopa.

LODOSYN is for use with levodopa in the occasional patient whose dosage requirement of carbidopa and levodopa necessitates separate titration of each entity. LODOSYN is used with carbidopa-levodopa or with levodopa to permit the administration of lower doses of levodopa with reduced nausea and vomiting, more rapid dosage titration, and with a somewhat smoother response. However, patients with markedly irregular ("on-off") responses to levodopa have not been shown to benefit from the addition of carbidopa.

Although the administration of LODOSYN permits control of parkinsonism and Parkinson's disease with much lower doses
'/>"/>

SOURCE Aton Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Satori Pharmaceuticals Adds Key Senior Members to its Leadership Team
2. MarketsandMarkets Partners With Eyeforpharma For The Pharma Forecasting Excellence Europe 2010 Summit
3. Mike Burgess Named Head of Oncology Discovery Translational Area for Roches Pharma Research and Early Development (pRED) Organization
4. Lotus Pharmaceuticals to Exhibit at the 63rd PHARMCHINA
5. Colorcon Acquires Pharmaceutical Excipient Company - NP Pharm
6. pHase Pharmaceuticals Announces New Venture
7. Ampio Pharmaceuticals to Acquire DMI Biosciences, Inc.
8. Sagent Pharmaceuticals Announces U.S. FDA Tentative Approval of Additional Adenosine Injection, USP Vial Presentations
9. Biostar Pharmaceuticals Approved for Listing on NASDAQ Global Market
10. Renhuang Pharmaceuticals Announces Continual Improvement in Days Sales Outstanding
11. Celtic Pharma Announces Initiation of Pediatric Dose Tolerance Trial Evaluating XERECEPT(R) in Pediatric Patients with Primary and Metastatic Brain Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB ... composition of matter, biological targets, mechanism of action, methods ... This patent application describes a novel class ... which interfere with the basic homeostatic cellular processes in ...
(Date:1/15/2014)... Jan. 15, 2014  According to Millennium Research Group ... intelligence, the United States ... markets will expand moderately through 2022, with embolization ... particular, increasing interest in drug-eluting beads (DEBs) and ...
(Date:1/15/2014)... Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... tender offer by its indirect wholly-owned subsidiary, Sapphire Subsidiary ... common stock of Solta Medical, Inc. (NASDAQ: ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
...  Aria Diagnostics, a molecular diagnostics company, today announced ... examines the accuracy of its non-invasive prenatal test ... Down syndrome) and Trisomy 18 (associated with Edwards ... with a proprietary algorithm to assess individualized risk ...
... Health Resource, Inc. (OTCBB: CHRI.OB News), announced today that ... of Gastrodia valued at 67.5 Million RMB or approximately ... Valley Pharm Corp and Sichuan Zhiyuanguanghe Pharm Corp and ... of Gastrodia from January 1, 2012 to December 31, 2012. ...
Cached Medicine Technology:Aria Announces Publication of Independent Study in the American Journal of Obstetrics & Gynecology Using Aria's Technology 2China Health Resource Signs Two New Agreements for the Sale of Gastrodia Valued at $10 Million USD (Corrected*) 2China Health Resource Signs Two New Agreements for the Sale of Gastrodia Valued at $10 Million USD (Corrected*) 3
(Date:4/24/2014)... Changes in managing patients before, during and after colorectal ... readmission rates, according to researchers who led a study ... practice, called enhanced recovery, is easier on patients before ... evacuation that are typically prescribed. After surgery, patients are ... possible, leading to faster recoveries. , Among findings published ...
(Date:4/24/2014)... epidemic of prescription opioid overdose deaths was outlined yesterday ... by leaders of agencies in the U.S. Department of ... health care providers to expand their use of medications ... describes a number of misperceptions that have limited access ... how medications can be used in combination with behavior ...
(Date:4/24/2014)... has found a relationship between motor skill deficiencies and ... in very young children. , The findings, believed ... relationship between motor skills and autism severity, indicate that ... included in treatment plans for young children with autism, ... of Public Health and Human Sciences. , "Recognizing ...
(Date:4/23/2014)... from healthy, unrelated donors was safe and effective ... by Clostridium difficile , according to a ... Diseases and available online. Known as fecal ... given via a colonoscope or a nasogastric tube. ... promising treatment more readily available to patients. , ...
(Date:4/23/2014)... is looking to give exercise enthusiasts the extra nudge ... shows that a cyber buddy can help. , The ... Journal , is the first to indicate that although ... exercise, a software-generated partner also can be effective. , ... can still motivate people to give greater effort while ...
Breaking Medicine News(10 mins):Health News:New approach for surgery patients cuts hospital stays and costs 2Health News:New approach for surgery patients cuts hospital stays and costs 3Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 3Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 4Health News:Motor skill deficiencies linked to autism severity in new research 2Health News:Pilot study suggests ways to widen access to fecal transplants for C. diff infections 2Health News:Cyber buddy is better than 'no buddy' 2
... compounds may explain the increased cases , FRIDAY, Nov. 6 ... volcano puts people at higher risk of getting a type ... might be related to cancer, but researchers suspect that the ... Researchers are also unsure of why thyroid cancer rates are ...
... , LAS VEGAS, Nov. 6 Cord Blood America, ... stem cell preservation company ( http://www.cordblood-america.com ... stem cells, a biological insurance policy for families nationwide ... laboratory in Las Vegas, and its recently refiled S1 ...
... ... NTSB Mandatory Sleep Apnea Testing Recommendations Are Expected To Become A Law ... Tracking Industry, A Sleep Apnea Lab Testing Could Cost About $2,000 With ... Diagnosed Apnea Patients Can Not Tolerate Standard CPAP Treatment. Dr. Jin Zhou ...
... Kids, American Cancer Society, American Cancer Society Cancer Action ... Legacy Foundation , WASHINGTON, Nov. 5 In ... in Kentucky today rejected a motion by tobacco companies ... the U.S. Food and Drug Administration (FDA) the power ...
... has Important Implications for Genetic Testing and Individualized Medicine , ... long QT syndrome (LQTS) study published in the ... genetic testing,s role in diagnosing disease, according to the senior ... pediatric cardiologist at Mayo Clinic, Dr. Ackerman directs Mayo,s Long ...
... Allied World Assurance,Company Holdings, Ltd (NYSE: AWH ) today ... the third quarter of 2009 compared to a net,loss of $46.4 ... Net income for the nine months ended September 30, 2009 ... of,$163.8 million, or $3.22 diluted share, for the first nine months ...
Cached Medicine News:Health News:Thyroid Cancer Higher in Volcanic Areas 2Health News:Cord Blood America Updates Advantages of Las Vegas Laboratory in Analyst Interview; Explains Recent S1 Filing 2Health News:SleepApneaUSA.net Announced An Immediate Alternative Sleep Apnea Solution In Response To The NTSB's Sleep Apnea Testing Recommendations 2Health News:SleepApneaUSA.net Announced An Immediate Alternative Sleep Apnea Solution In Response To The NTSB's Sleep Apnea Testing Recommendations 3Health News:SleepApneaUSA.net Announced An Immediate Alternative Sleep Apnea Solution In Response To The NTSB's Sleep Apnea Testing Recommendations 4Health News:SleepApneaUSA.net Announced An Immediate Alternative Sleep Apnea Solution In Response To The NTSB's Sleep Apnea Testing Recommendations 5Health News:Federal Judge Rejects Tobacco Companies' Effort to Block Key Provisions of New Tobacco Regulation Law 2Health News:Research Findings Key for Understanding, Interpreting Genetic Testing for Long QT Syndrome 2Health News:Research Findings Key for Understanding, Interpreting Genetic Testing for Long QT Syndrome 3Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 2Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 3Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 4Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 5Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 6Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 7Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 8Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 9Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 10Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 11Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 12Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 13Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 14Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 15Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 16Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 17Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 18
5 mm curved hook with markings at 14 mm and 20 mm from tip. Flat serrated handle with polished finish. Overall length: 4.7 inches....
Flattened hook. Flat serrated handle with polished finish. Hook: #1 size 8 mm. Overall length: 5.3 inches....
7 mm flattened hook. Flat serrated handle with polished finish. Overall length: 4.9 inches....
Flattened 13 mm "Graefe type" hook, with 1.5 mm oval hole. Flat serrated handle with polished finish. Overall length: 5.6 inches....
Medicine Products: